Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
338 participants
INTERVENTIONAL
2005-09-30
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia
NCT05693935
An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia
NCT00728195
Phase IIA Study in Patients With Schizophrenia
NCT00686998
A Study of Olanzapine in Patients With Schizophrenia
NCT00970281
Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
NCT00088478
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SB-773812
Olanzapine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PANSS total score of at least 70 at Screen and Baseline and a minimum score of 4 (moderate) on at least 2 of the following: conceptual disorganization (P2) hallucinatory behaviour (P3) suspiciousness (P6) or unusual thought content (G9) at the Screen and Baseline visits
Exclusion Criteria
* Bipolar disorder, a history of substance dependence, or a medical or psychiatric disorder that would interfere with the accurate assessment of safety or efficacy are not eligible.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Cerritos, California, United States
GSK Investigational Site
Garden Grove, California, United States
GSK Investigational Site
National City, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Upland, California, United States
GSK Investigational Site
New Haven, Connecticut, United States
GSK Investigational Site
Washington D.C., District of Columbia, United States
GSK Investigational Site
North Miami, Florida, United States
GSK Investigational Site
Clementon, New Jersey, United States
GSK Investigational Site
Kenilworth, New Jersey, United States
GSK Investigational Site
Albuquerque, New Mexico, United States
GSK Investigational Site
Orangeburg, New York, United States
GSK Investigational Site
Butner, North Carolina, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Bellaire, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Falls Church, Virginia, United States
GSK Investigational Site
Liège, , Belgium
GSK Investigational Site
Montignies-sur-Sambre, , Belgium
GSK Investigational Site
San José, , Costa Rica
GSK Investigational Site
Brno, , Czechia
GSK Investigational Site
Lnáře, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Ahmedabad, , India
GSK Investigational Site
Bangalore, , India
GSK Investigational Site
Bangalore, , India
GSK Investigational Site
Bangalore, , India
GSK Investigational Site
Hyderabad, , India
GSK Investigational Site
Lucknow, , India
GSK Investigational Site
Ludhiana, , India
GSK Investigational Site
Mangalore, , India
GSK Investigational Site
Pune, , India
GSK Investigational Site
Tirupati, , India
GSK Investigational Site
Lima, Lima Province, Peru
GSK Investigational Site
Leningraskaya Region, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Nizhny Novgorod, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Smolensk, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NAA104606
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.